| Name | Title | Contact Details |
|---|
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio`s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world`s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin`s lymphoma, acute myeloid leukemia and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE™) platform technology.
Corbus Pharmaceuticals Holdings, Inc.is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Epigentek is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Omeros Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.